Provexis PLC (PXS), the AIM-quoted developer and licensor of the proprietary Fruitflow® heart-health functional food ingredient, has announced that all seven resolutions tabled at its Annual General Meeting on 20 November 2026 were passed. Shareholder support across all resolutions exceeded 98%, with the closest vote recording 98.94% in favour. The result signals continued broad shareholder confidence in the company's board and strategy as Provexis pursues commercial opportunities for Fruitflow in China and direct-to-consumer sales in the UK.
Key Points
- Provexis PLC (PXS) is an AIM-quoted functional food ingredient developer headquartered in Reading, Berkshire.
- All seven resolutions at the 20 November 2026 AGM were duly passed by proxy vote.
- Resolution 1 received the highest support at 99.82% in favour; Resolution 7 the lowest at 98.94% in favour.
- Investors may be watching for updates on BYHEALTH's regulatory applications in China and progress with Fruitflow product registrations.
All Seven Resolutions Passed at Provexis 2026 Annual General Meeting
At the AGM held on 20 November 2026, Provexis confirmed that every resolution submitted to shareholders was approved. Resolution 1 achieved the strongest backing, with 333,612,641 votes cast in favour, representing 99.82% of votes counted. Resolution 7 attracted the highest opposition, with 3,528,375 votes against, equating to 1.06% of votes cast. The company's announcement notes that withheld votes are not counted in the calculation of the proportion of votes for or against any resolution, in line with standard UK corporate governance practice.
Fruitflow® Ingredient: EFSA-Approved Antiplatelet Science Behind Provexis's Revenue Model
Provexis develops, licenses, and sells Fruitflow®, a highly concentrated natural ingredient derived from tomatoes that contains over 30 known anti-platelet compounds and is lyophilised to be lycopene-free. The European Food Safety Authority has approved a health claim stating that 150mg of Fruitflow helps maintain normal platelet aggregation, contributing to healthy blood flow. Provexis generates revenue through ingredient licensing and direct consumer sales of its Fruitflow Plus dietary supplement, available via its own website and Amazon.co.uk, positioning it within the growing functional food and cardiovascular health sector.
BYHEALTH China Partnership and Regulatory Applications Remain a Key Commercial Watch Point
A material strand of Provexis's commercial strategy involves its long-standing relationship with BYHEALTH, a circa £2 billion listed Chinese dietary supplement business. The two companies have collaborated for more than ten years, with BYHEALTH investing tens of millions of RMB in eight separate Fruitflow clinical studies conducted in China. In August 2023, Provexis reported that BYHEALTH had submitted its first application for a new permitted health function claim and related product registration applications to China's State Administration for Market Regulation. Investors may be watching for further regulatory developments from these submissions as a potential catalyst for Provexis's licensing revenues.
Provexis Board Contacts and Nominated Adviser Following AGM Result
Following the AGM outcome, Provexis Chairman Dawson Buck and Chief Executive Ian Ford remain the named board contacts for investor and media enquiries. Allenby Capital Limited, represented by Nick Naylor, Liz Kirchner, and Ashur Joseph, continues to act as the company's nominated adviser and broker. The company was founded in 1999 and its shares are traded on the AIM market of the London Stock Exchange under the ticker symbol PXS.



Please wait processing your request...